OBJECTIVE: This discussion document about the management of cancer pain is written from the pain specialists' perspective in order to provoke thought and interest in a multimodal approach to the management of cancer pain, not just towards the end of life, but pain at diagnosis, as a consequence of cancer therapies, and in cancer survivors. It relates the science of pain to the clinical setting and explains the role of psychological, physical, interventional and complementary therapies in cancer pain. METHODS: This document has been produced by a consensus group of relevant healthcare professionals in the United Kingdom and patients' representatives making reference to the current body of evidence relating to cancer pain. In the second of two parts, physical, invasive and complementary cancer pain therapies; treatment in the community; acute, treatment-related and complex cancer pain are considered. CONCLUSIONS: It is recognized that the World Health Organization (WHO) analgesic ladder, whilst providing relief of cancer pain towards the end of life for many sufferers world-wide, may have limitations in the context of longer survival and increasing disease complexity. To complement this, it is suggested that a more comprehensive model of managing cancer pain is needed that is mechanism-based and multimodal, using combination therapies including interventions where appropriate, tailored to the needs of an individual, with the aim to optimize pain relief with minimization of adverse effects.
OBJECTIVE: This discussion document about the management of cancer pain is written from the pain specialists' perspective in order to provoke thought and interest in a multimodal approach to the management of cancer pain, not just towards the end of life, but pain at diagnosis, as a consequence of cancer therapies, and in cancer survivors. It relates the science of pain to the clinical setting and explains the role of psychological, physical, interventional and complementary therapies in cancer pain. METHODS: This document has been produced by a consensus group of relevant healthcare professionals in the United Kingdom and patients' representatives making reference to the current body of evidence relating to cancer pain. In the second of two parts, physical, invasive and complementary cancer pain therapies; treatment in the community; acute, treatment-related and complex cancer pain are considered. CONCLUSIONS: It is recognized that the World Health Organization (WHO) analgesic ladder, whilst providing relief of cancer pain towards the end of life for many sufferers world-wide, may have limitations in the context of longer survival and increasing disease complexity. To complement this, it is suggested that a more comprehensive model of managing cancer pain is needed that is mechanism-based and multimodal, using combination therapies including interventions where appropriate, tailored to the needs of an individual, with the aim to optimize pain relief with minimization of adverse effects.
Authors: Eva Mazzotti; Gian Carlo Antonini Cappellini; Stefania Buconovo; Roberto Morese; Alessandro Scoppola; Claudia Sebastiani; Paolo Marchetti Journal: Support Care Cancer Date: 2012-01-21 Impact factor: 3.603
Authors: Michelle A Fortier; Sun Yang; Michael T Phan; Daniel M Tomaszewski; Brooke N Jenkins; Zeev N Kain Journal: Pediatr Blood Cancer Date: 2019-12-18 Impact factor: 3.167
Authors: Crystal S Denlinger; Jennifer A Ligibel; Madhuri Are; K Scott Baker; Wendy Demark-Wahnefried; Debra L Friedman; Mindy Goldman; Lee Jones; Allison King; Grace H Ku; Elizabeth Kvale; Terry S Langbaum; Kristin Leonardi-Warren; Mary S McCabe; Michelle Melisko; Jose G Montoya; Kathi Mooney; Mary Ann Morgan; Javid J Moslehi; Tracey O'Connor; Linda Overholser; Electra D Paskett; Muhammad Raza; Karen L Syrjala; Susan G Urba; Mark T Wakabayashi; Phyllis Zee; Nicole McMillian; Deborah Freedman-Cass Journal: J Natl Compr Canc Netw Date: 2014-04 Impact factor: 11.908
Authors: Adam Hurlow; Michael I Bennett; Karen A Robb; Mark I Johnson; Karen H Simpson; Stephen G Oxberry Journal: Cochrane Database Syst Rev Date: 2012-03-14
Authors: Tara Sanft; Crystal S Denlinger; Saro Armenian; K Scott Baker; Gregory Broderick; Wendy Demark-Wahnefried; Debra L Friedman; Mindy Goldman; Melissa Hudson; Nazanin Khakpour; Divya Koura; Robin M Lally; Terry S Langbaum; Allison L McDonough; Michelle Melisko; Kathi Mooney; Halle C F Moore; Javid J Moslehi; Tracey O'Connor; Linda Overholser; Electra D Paskett; Lindsay Peterson; William Pirl; M Alma Rodriguez; Kathryn J Ruddy; Sophia Smith; Karen L Syrjala; Amye Tevaarwerk; Susan G Urba; Phyllis Zee; Nicole R McMillian; Deborah A Freedman-Cass Journal: J Natl Compr Canc Netw Date: 2019-07-01 Impact factor: 11.908
Authors: Robert A Swarm; Amy Pickar Abernethy; Doralina L Anghelescu; Costantino Benedetti; Sorin Buga; Charles Cleeland; Oscar A Deleon-Casasola; June G Eilers; Betty Ferrell; Mark Green; Nora A Janjan; Mihir M Kamdar; Michael H Levy; Maureen Lynch; Rachel M McDowell; Natalie Moryl; Suzanne A Nesbit; Judith A Paice; Michael W Rabow; Karen L Syrjala; Susan G Urba; Sharon M Weinstein; Mary Dwyer; Rashmi Kumar Journal: J Natl Compr Canc Netw Date: 2013-08 Impact factor: 11.908